stocks logo

BMRN Valuation

BioMarin Pharmaceutical Inc
$
58.140
-0.87(-1.474%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings

BMRN Relative Valuation

BMRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMRN is overvalued; if below, it's undervalued.

Historical Valuation

BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.87 is considered Undervalued compared with the five-year average of 45.20. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 87.52 to 259.61 according to relative valuation methord. Compared to the current price of 59.01 USD , BioMarin Pharmaceutical Inc is Undervalued By 32.57%.
Relative Value
Fair Zone
87.52-259.61
Current Price:59.01
32.57%
Undervalued
13.87
PE
1Y
3Y
5Y
Trailing
Forward
10.95
EV/EBITDA
BioMarin Pharmaceutical Inc. (BMRN) has a current EV/EBITDA of 10.95. The 5-year average EV/EBITDA is 78.09. The thresholds are as follows: Strongly Undervalued below -163.44, Undervalued between -163.44 and -42.67, Fairly Valued between 198.86 and -42.67, Overvalued between 198.86 and 319.63, and Strongly Overvalued above 319.63. The current Forward EV/EBITDA of 10.95 falls within the Historic Trend Line -Fairly Valued range.
13.44
EV/EBIT
BioMarin Pharmaceutical Inc. (BMRN) has a current EV/EBIT of 13.44. The 5-year average EV/EBIT is -17.14. The thresholds are as follows: Strongly Undervalued below -281.15, Undervalued between -281.15 and -149.15, Fairly Valued between 114.86 and -149.15, Overvalued between 114.86 and 246.87, and Strongly Overvalued above 246.87. The current Forward EV/EBIT of 13.44 falls within the Historic Trend Line -Fairly Valued range.
3.50
PS
BioMarin Pharmaceutical Inc. (BMRN) has a current PS of 3.50. The 5-year average PS is 6.61. The thresholds are as follows: Strongly Undervalued below 3.57, Undervalued between 3.57 and 5.09, Fairly Valued between 8.13 and 5.09, Overvalued between 8.13 and 9.64, and Strongly Overvalued above 9.64. The current Forward PS of 3.50 falls within the Strongly Undervalued range.
10.79
P/OCF
BioMarin Pharmaceutical Inc. (BMRN) has a current P/OCF of 10.79. The 5-year average P/OCF is 38.95. The thresholds are as follows: Strongly Undervalued below -33.71, Undervalued between -33.71 and 2.62, Fairly Valued between 75.28 and 2.62, Overvalued between 75.28 and 111.61, and Strongly Overvalued above 111.61. The current Forward P/OCF of 10.79 falls within the Historic Trend Line -Fairly Valued range.
15.09
P/FCF
BioMarin Pharmaceutical Inc. (BMRN) has a current P/FCF of 15.09. The 5-year average P/FCF is 36.00. The thresholds are as follows: Strongly Undervalued below 9.13, Undervalued between 9.13 and 22.57, Fairly Valued between 49.43 and 22.57, Overvalued between 49.43 and 62.87, and Strongly Overvalued above 62.87. The current Forward P/FCF of 15.09 falls within the Undervalued range.
BioMarin Pharmaceutical Inc (BMRN) has a current Price-to-Book (P/B) ratio of 1.95. Compared to its 3-year average P/B ratio of 3.18 , the current P/B ratio is approximately -38.66% higher. Relative to its 5-year average P/B ratio of 3.37, the current P/B ratio is about -42.11% higher. BioMarin Pharmaceutical Inc (BMRN) has a Forward Free Cash Flow (FCF) yield of approximately 5.52%. Compared to its 3-year average FCF yield of 1.36%, the current FCF yield is approximately 305.24% lower. Relative to its 5-year average FCF yield of 1.06% , the current FCF yield is about 422.67% lower.
1.95
P/B
Median3y
3.18
Median5y
3.37
5.52
FCF Yield
Median3y
1.36
Median5y
1.06

Competitors Valuation Multiple

The average P/S ratio for BMRN's competitors is 7.24, providing a benchmark for relative valuation. BioMarin Pharmaceutical Inc Corp (BMRN) exhibits a P/S ratio of 3.50, which is -51.62% above the industry average. Given its robust revenue growth of 14.84%, this premium appears unsustainable.

Performance Decomposition

1Y
3Y
5Y
Market capitalization of BMRN decreased by 31.06% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 13.66 to 24.92.
The secondary factor is the Revenue Growth, contributed 14.84%to the performance.
Overall, the performance of BMRN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
14.84%
648.83M → 745.15M
Revenue Growth
+
82.43%
13.66 → 24.92
Margin Expansion
+
-128.33%
-76.99 → 21.81
P/E Change
=
-31.06%
84.33 → 58.14
Mkt Cap Growth

FAQ

arrow icon

Is BioMarin Pharmaceutical Inc (BMRN) currently overvalued or undervalued?

BioMarin Pharmaceutical Inc (BMRN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 13.87 is considered Undervalued compared with the five-year average of 45.20. The fair price of BioMarin Pharmaceutical Inc (BMRN) is between 87.52 to 259.61 according to relative valuation methord. Compared to the current price of 59.01 USD , BioMarin Pharmaceutical Inc is Undervalued By 32.57% .
arrow icon

What is BioMarin Pharmaceutical Inc (BMRN) fair value?

arrow icon

How does BMRN's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for BioMarin Pharmaceutical Inc (BMRN) as of Jul 29 2025?

arrow icon

What is the current FCF Yield for BioMarin Pharmaceutical Inc (BMRN) as of Jul 29 2025?

arrow icon

What is the current Forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN) as of Jul 29 2025?

arrow icon

What is the current Forward P/S ratio for BioMarin Pharmaceutical Inc (BMRN) as of Jul 29 2025?